Whitehead Institute for Biomedical Research

Whitehead Institute for Biomedical Research

Whitehead Institute for Biomedical Research

Overview
Date Founded

1982

Headquarters

455 Main Street, Cambridge, MA, 02142, USA

Charitable Causes

Biological & Life Science Research
Philanthropy, Voluntarism, and Grantmaking Foundations
Higher Education & Universities
Medical Research
Education Research & Support

Employees (Worldwide)

439

Industries

Biotechnology
Other Business & Consulting Services
Market & Policy Research
Hospitals & Patient Services
Medical Support Services

Company Description

Whitehead Institute is a world-renowned non-profit research institution dedicated to improving human health through basic biomedical research. By cultivating a deeply collaborative culture and enabling the pursuit of bold, creative inquiry, Whitehead fosters paradigm-shifting scientific achievement. For more than 30 years, Whitehead faculty have delivered breakthroughs that have transformed our understanding of biology and accelerated development of therapies for such diseases as Alzheimer’s, Parkinson’s, diabetes, and certain cancers. Located in Cambridge, Massachusetts, Whitehead Institute was founded in 1982 by businessman and philanthropist Edwin C. “Jack” Whitehead.

Contact Data
Trying to get in touch with decision makers at Whitehead Institute for Biomedical Research? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
In The News
Targeted News Service
December 6, 2019
The Surprising Individuality of MicroRNAs
The Boston Globe
November 29, 2019
2019 WUNDERKINDS
Targeted News Service
November 23, 2019
Whitehead Institute: Building a Roadmap for Salicylic Acid
Targeted News Service
November 21, 2019
Whitehead Institute: Committed to Reproduction
Executives & Employees

Founding Member

Founding Member

Assistant Secretary (Until DEC)

Faculty Member

Faculty Member

President & Director

Chief Financial Officer

Partner

Board of Directors

Managing Partner at The Partners of '63, Inc.

Member of the Executive Committee, MIT Corporation at Massachusetts Institute of Technology

Co-Founder at Alnylam Pharmaceuticals, Inc.

Founder at Alnylam Pharmaceuticals, Inc.

Founder at AlphaSimplex Group LLC

President & Director at Whitehead Institute for Biomedical Research

Member, Council for the Arts at Massachusetts Institute of Technology

Fund Advisor at Putnam Investment Management LLC

Partner at Whitehead Group Ltd.

Senior Advisor at TA Associates Management, L.P.

Distinguished Alumni
Brenda Schulman is now Co-Leader, Cancer Genetics, Biochemistry & Cell Biology Program at St. Jude Children's Research Hospital, Inc.
Paths to Whitehead Institute for Biomedical Research
Potential Connections via
Relationship Science
You
Whitehead Institute for Biomedical Research
Advisors & Consultants
Investment Manager

Bain Capital LP engages in provision of investment consulting services. The firm specializes in private equity, public equity, fixed income and credit, venture capital, and return investments management across multiple sectors, industries, and sector classes. The company was founded in 1984 and is headquartered in Boston, MA.

Investment Manager

The Investment Fund for Foundations (TIFF) invests primarily in private equity funds of funds.

Investment Manager

CGTC employs a long-term investment approach that is based on rigorous fundamental research. The firm uses a system of multiple portfolio managers in managing most separate account and fund assets. Under this approach, the portfolio of an account or fund is divided into segments managed by individual managers who decide how their respective segments will be invested. In addition, investment analysts may make investment decisions with respect to a portion of the portfolio. The firm offers equity, fixed-income, balanced, and other customized investment strategies based on the investment objectives of CGTC clients. CGTC's equity strategies include: US Equity, International Equity, Global Equity, All Country World Equity, International All Countries Equity, and Emerging Markets Equity. The firm's fixed-income strategies include: US Core Fixed-Income, Long Duration Government, Long Duration Credit, US High-Yield, International Fixed-Income, Global Fixed-Income, Global High-Income Opportunities, and Emerging Markets Debt. CGTC's balanced and total opportunities strategies include: US Balanced, Global Balanced, Absolute Income Grower, World Dividend Growers, and Emerging Markets Total Opportunities.

Legal Advisor

Partner at Milbank LLP

Legal Advisor

Partner at Kirkland & Ellis LLP

Clients

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan and is headquartered in Cambridge, MA.

Key Stats and Financials As of 2016
Market Capitalization
Total Enterprise Value
Earnings Per Share
Revenue
$55.9M
Non-Profit Donations & Grants
$10K - $25K
2016
$10K - $25K
2014
Non-Profit Donations & Grants Received
$52K
12/31/2016
$150K
12/31/2016
$45K
09/30/2016
Suppliers
J. C. Cannistraro LLC Engineering, Construction & Architecture | Watertown, MA

Wolf, Greenfield & Sacks PC Internet Software & Services | Boston, Massachusetts

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Whitehead Institute for Biomedical Research. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Whitehead Institute for Biomedical Research's profile does not indicate a business or promotional relationship of any kind between RelSci and Whitehead Institute for Biomedical Research.